JAM
KPTI icon

Jupiter Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Jupiter Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,974
Closed -$1.01M – 585
2022
Q2 		$1.01M Buy
+14,974
New +$1.37M 0.01% 428

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Jupiter Asset Management's KPTI Position: Q3 2022 in Review

Jupiter Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2022, closing a stake of 14,974 shares — an estimated $1.01M sold.

Jupiter Asset Management first reported a position in KPTI in Q2 2022 and held it in 1 quarter. The position peaked at $1.01M in Q2 2022. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

  • Jupiter Asset Management reported no remaining Karyopharm Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Jupiter Asset Management sold 14,974 Karyopharm Therapeutics shares in Q3 2022, an estimated $1.01M.
  • Jupiter Asset Management first reported a position in Karyopharm Therapeutics in Q2 2022 and held it in 1 quarter.
  • Jupiter Asset Management's Karyopharm Therapeutics position peaked at $1.01M in Q2 2022.
  • 147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on Jupiter Asset Management's 13F filing for Q3 2022, filed 10 Nov 2022.